With the advancement of medicine, our population is undergoing a prolonged aging process. Over the next three decades, the global population aged over 65 years is set to more than double, reaching a staggering 1.5 billion individuals. The emergence of the gut microbiota as a potent modulator of healthy aging requires a concerted effort to allocate resources and research towards developing interventions aimed at promoting optimal gut health and longevity.
Protist Tritrichomonas arnold protects against viral-induced gluten intolerance
18 Dec 2023by Heather Galipeau, Mark Wulczynski
Celiac disease is a chronic immune-mediated enteropathy that may be unleashed by enteric viral infections. However, new findings in mice identified a commensal protist, Tritrichomonas arnold, that protects against reovirus-induced intolerance to gluten by counteracting virus-induced proinflammatory dendritic cell activation.
Explore cutting-edge research on the gut microbiome with the GMFH 2022 Year at a Glance report
21 Feb 2023by GMFH Editing Team
Significant strides have been made in our comprehension of the role of the gut microbiome in health and disease throughout the year 2022. We invite you to take a closer look at the "2022 Year at a Glance" report and learn about the groundbreaking discoveries made.
Fecal microbiota transplantation: From clinical trials to market, where are we now?
7 Feb 2023by Andreu Prados
While fecal microbiota transplants are recommended for multiple recurrent Clostridioides difficile infection, their use in clinical practice is hindered by a lack of regulation and understanding of the underlying ecological dynamics. This article covers major challenges for the treatment in transitioning from bench to bedside, from the scientific, clinical and regulatory perspectives (Part 6).
The role of the gut mycobiota in influencing the immune system and inflammation-related diseases
12 Jan 2023by Andreu Prados
Gut fungi found in the lower gastrointestinal tract can influence the host immune system just like the bacterial microbiota. This article focuses on the role of the gut mycobiota in immune system homeostasis and its relevance for host health.
What are the factors that predict complications associated with Clostridioides difficile infection and what can be done in clinical practice?
21 Nov 2022by Andreu Prados
Clostridioides difficile infection is a common cause of diarrhea in both the hospital and community settings, with C. difficile recurrence one of the most challenging outcomes to address. This article focuses on the factors that predict long-term complications of C. difficile infection and what can be done in clinical practice to minimize them (Part 5).
November, Clostridioides difficile infection awareness month
11 Nov 2022by Konstantina Zafeiropoulou
Just one month before friends and families gather around the Christmas table, November is here to bring awareness around Clostridioides difficile infection, and the importance of microbiota-derived treatments. With this post, all of us in GMFH aim to highlight the importance of protecting ourselves and families and stopping the spread of this potentially deadly infection.
Fecal transplants and defined commensal consortia: the pros and cons of restoring the gut microbiome in recurrent Clostridioides difficile infection
19 Sep 2022by Andreu Prados
Correcting the altered gut microbiome is an important goal in Clostridioides difficile management, but the matter is not addressed by mainstream treatments with antibiotics. This article focuses on where fecal microbiota transplantation and investigational microbiota-based therapeutics stand for C. difficile infection (Part 3)
How can you accurately diagnose and manage Clostridioides difficile infection?
10 Jun 2022by Andreu Prados
Clostridioides difficile infection is a common cause of diarrhea, not only in hospitals but also in outpatient settings. This article focuses on the diagnosis and treatment of C. difficile infection and includes an updated summary of literature on the latest guidelines (Part 2).
Probiotics with an anti-inflammatory effect may reduce abdominal pain and hours of hospitalization in adult patients with acute uncomplicated diverticulitis
19 Apr 2022by Andreu Prados
The involvement of the gut microbiota in diverticulitis is gaining interest. This article explores what we know so far about the role of the gut microbiota in diverticulitis and discusses two recent clinical trials on the role of probiotics in managing acute uncomplicated diverticulitis.